The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.
 
Daniel Shao-Weng Tan
Consulting or Advisory Role - Boston Biomedical; Novartis
Research Funding - Novartis
 
Takashi Seto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Fuji Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Natasha B. Leighl
Research Funding - Roche Canada (Inst)
 
Gregory J. Riely
Honoraria - Celgene
Consulting or Advisory Role - ARIAD; Mersana; Novartis; Roche
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Novartis
 
Lecia V. Sequist
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Genentech; GlaxoSmithKline; Merrimack; Novartis; Taiho Pharmaceutical
Research Funding - ArQule (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Enriqueta Felip
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Pfizer; Roche Pharma AG
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis
 
Juergen Wolf
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; MSD; Novartis; Pfizer; Roche Pharma AG
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Clovis Oncology; Daiichi Sankyo; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Takeda (Inst)
Research Funding - Boehringer Ingelheim (Inst)
 
Igor Matushansky
Employment - Novartis
 
Xiaolu Yu
Employment - Novartis
 
Shu-Fang Hsu Schmitz
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Xiaoming Cui
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Dong-Wan Kim
Consulting or Advisory Role - Novartis